新検索ページはこちら
ログイン
お問い合わせ
（旧版）科学的根拠に基づく糖尿病診療ガイドライン 改訂第2版
書誌情報
引用文献
8．糖尿病腎症の治療
文献
| 1） | The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977-86. レベル1 |
| 2） | Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329(5):304-9. レベル2 |
| 3） | Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103-17. レベル2 |
| 4） | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53. レベル1 |
| 5） | Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F, Spalluto A, Vanasia A, Villa GM, Nosadini R. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care. 1998;21(1):104-10. レベル2 |
| 6） | Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group. Diabetologia. 1996;39(5):587-93. レベル2 |
| 7） | Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med. 1995;99(5):497-504. レベル2 |
| 8） | Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 1994;271(4):275-9. レベル2 |
| 9） | Katayama S, Kikkawa R, Isogai S, Sasaki N, Matsuura N, Tajima N, Urakami T, Uchigata Y, Ohashi Y. Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). Diabetes Res Clin Pract. 2002;55(2):113-21. レベル2－ |
| 10） | ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med. 2001;134(5):370-9. レベル2＋ |
| 11） | Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):703-13. レベル1 |
| 12） | Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):713-20. レベル1 |
| 13） | Schnack C, Hoffmann W, Hopmeier P, Schernthaner G. Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. Diabetologia. 1996;39(12):1611-6. レベル2 |
| 14） | Shiba T, Inoue M, Tada H, Hayashi Y, Okuda Y, Fujita R, Makino F, Takahasi C, Kageyama S, Kitamura S, Iwamoto Y. Delapril versus manidipine in hypertensive therapy to halt the type-2-diabetes-mellitus-associated nephropathy. Diabetes Res Clin Pract. 2000;47(2):97-104. レベル2－ |
| 15） | Agardh CD, Garcia-Puig J, Charbonnel B, Angelkort B, Barnett AH. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens. 1996;10(3):185-92. レベル2 |
| 16） | Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355(9200):253-9. レベル1 |
| 17） | Velussi M, Brocco E, Frigato F, Zolli M, Muollo B, Maioli M, Carraro A, Tonolo G, Fresu P, Cernigoi AM, Fioretto P, Nosadini R. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes. 1996;45(2):216-22. レベル2－ |
| 18） | Baba S; J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract. 2001;54(3):191-201. レベル2 |
| 19） | Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870-8. レベル1 |
| 20） | Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941-51. Epub 2004 Oct 31. レベル1 |
| 21） | Sano T, Kawamura T, Matsumae H, Sasaki H, Nakayama M, Hara T, Matsuo S, Hotta N, Sakamoto N. Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care. 1994;17(5):420-4. レベル2－ |
| 22） | Sano T, Hotta N, Kawamura T, Matsumae H, Chaya S, Sasaki H, Nakayama M, Hara T, Matsuo S, Sakamoto N. Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomized study. Diabet Med. 1996;13(2):120-4. レベル2－ |
| 23） | Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118(8):577-81. レベル2－ |
| 24） | Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;128(12 Pt 1):982-8. レベル2 |
| 25） | Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care. 1997;20(10):1576-81. レベル2 |
| 26） | Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456-62. レベル1 |
| 27） | Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis. 1999;34(5):809-17. レベル2 |
| 28） | Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-60. レベル1 |
| 29） | Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-9. レベル1 |
| 30） | Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351(19):1952-61. Epub 2004 Oct 31. レベル1 |
| 31） | Haneda M, Kikkawa R, Sakai H, Kawamori R; Candesartan in Diabetic Nephropathy Study Group. Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy. Diabetes Res Clin Pract. 2004;66(1):87-95. レベル2 |
| 32） | Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1991;324(2):78-84. レベル2－ |
| 33） | Brouhard BH, LaGrone L. Effect of dietary protein restriction on functional renal reserve in diabetic nephropathy. Am J Med. 1990;89(4):427-31. レベル2－ |
| 34） | Dullaart RP, Beusekamp BJ, Meijer S, van Doormaal JJ, Sluiter WJ. Long-term effects of protein-restricted diet on albuminuria and renal function in IDDM patients without clinical nephropathy and hypertension. Diabetes Care. 1993;16(2):483-92. レベル2－ |
| 35） | Raal FJ, Kalk WJ, Lawson M, Esser JD, Buys R, Fourie L, Panz VR. Effect of moderate dietary protein restriction on the progression of overt diabetic nephropathy: a 6-mo prospective study. Am J Clin Nutr. 1994;60(4):579-85. レベル2－ |
| 36） | Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int. 2002;62(1):220-8. レベル2 |
| 37） | Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med. 1996;124(7):627-32. レベル2＋ |
| 38） | Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis. 1998;31(6):954-61. レベル2＋ |
| 39） | Waugh NR, Robertson AM. Protein restriction for diabetic renal disease. Cochrane Database Syst Rev. 2000;(2):CD002181. レベル2＋ |
| 40） | Pijls LT, de Vries H, Donker AJ, van Eijk JT. The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Nephrol Dial Transplant. 1999;14(6):1445-53. レベル2 |
| 41） | Araki S, Haneda M, Sugimoto T, Isono M, Isshiki K, Kashiwagi A, Koya D. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes. 2005;54(10):2983-7. レベル3 |
| 42） | Yamada T, Komatsu M, Komiya I, Miyahara Y, Shima Y, Matsuzaki M, Ishikawa Y, Mita R, Fujiwara M, Furusato N, Nishi K, Aizawa T. Development, progression, and regression of microalbuminuria in Japanese patients with type 2 diabetes under tight glycemic and blood pressure control: the Kashiwa study. Diabetes Care. 2005;28(11):2733-8. レベル3 |
| 43） | Nielsen FS, Rossing P, Gall MA, Skøtt P, Smidt UM, Parving HH. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes. 1997;46(7):1182-8. レベル2－ |
| 44） | Liou HH, Huang TP, Campese VM. Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases. Nephron. 1995;69(1):41-8. レベル2－ |
| 45） | Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996;50(5):1641-50. レベル2－ |
| 46） | Yokoyama H, Tomonaga O, Hirayama M, Ishii A, Takeda M, Babazono T, Ujihara U, Takahashi C, Omori Y. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia. 1997;40(4):405-11. レベル3 |
| 47） | Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R; RENAAL Study Investigators. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003;63(4):1499-507. レベル1 |
| 48） | Wilmer WA, Hebert LA, Lewis EJ, Rohde RD, Whittier F, Cattran D, Levey AS, Lewis JB, Spitalewitz S, Blumenthal S, Bain RP. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis. 1999;34(2):308-14. レベル6 |
| 49） | Rossing K, Christensen PK, Hovind P, Parving HH. Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients. Diabetologia. 2005;48(11):2241-7. Epub 2005 Sep 17. レベル3 |
【参考文献】
| a） | 日本腎臓学会 編．腎疾患の生活指導・食事療法ガイドライン．東京医学社．東京．1998. |
| b） | Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH; American Diabetes Association. Diabetic nephropathy. Diabetes Care. 2003;26 Suppl 1:S94-8. |
| c） | 日本糖尿病学会 編．糖尿病治療ガイド 2006-2007．文光堂．東京．2006. |
| d） | 猪股茂樹，羽田勝計，守屋達美，片山茂裕，岩本安彦，堺 秀人，富野康日己，松尾清一，浅野 泰，槇野博史，日本糖尿病学会・日本腎臓学会糖尿病性腎症合同委員会．糖尿病性腎症の新しい早期診断基準．糖尿病．2005;48(10):757-9. |
| e） | 慢性腎臓病対策委員会．特集 慢性腎臓病（CKD）．日本腎臓学会誌．2006;48:688-722. |
| f） | Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36(3):646-61. |
| g） | 繁田幸男，田村忠雄，中本 安，他．糖尿病性腎症病期分類．総括研究報告糖尿病性腎症に関する研究．厚生省平成3年度糖尿病調査研究報告書．1992;317-20. |
| h） | 繁田幸男，二瓶 宏，木田 寛，他．総括研究報告糖尿病性腎症に関する研究．腎症に関する食事療法基準の作成．厚生省平成4年度糖尿病調査研究報告書．1993;353-6. |
| i） | 日本腎臓学会 編．腎機能（GFR）・尿蛋白測定ガイドライン．東京医学社．東京．2003. |
| j） | 日本透析医学会．我が国の慢性透析療法の現状，2002． |
| k） | Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999;341(15):1127-33. |
| l） | 日本高血圧学会高血圧治療ガイドライン作成委員会 編．高血圧治療ガイドライン2004．ライフサイエンス出版．東京．2004. |
| m） | Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164-76. |
